HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in BJP Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by DUGGAN, A. Articles by KERWIN, R. Search for Related Content PubMed PubMed Citation Articles by DUGGAN, A. Articles by KERWIN, R.

Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK

Abacus International, Bicester

MARTIN KNAPP, PhD and ROBERT KERWIN, FRCPsych

Institute of Psychiatry, London, UK

Correspondence: Juliet Warner, Abacus International, 3–4 Market Square, Bicester OX26 6AA, UK

Declaration of interest This project was sponsored by Novartis Pharmaceuticals UK Ltd.

Background Schizophrenia is a major cause of suicide, and symptoms characteristic of treatment-resistant disease are strong risk factors. Clozapine reduces symptoms in 60% of such patients and significantly decreases the risk of suicide.

Aims To model the impact of increased clozapine prescribing on lives saved and resource utilisation.

Method A model was built to compare current levels of clozapine prescribing with a scenario in which all suitable patients with treatment-resistant schizophrenia received clozapine.

Results It was estimated that an average of 53 lives could be saved in the UK each year. If clozapine is cost-neutral, the cost per life-year saved is £5108. If clozapine achieves a 10% reduction in annual support costs, the net saving is £8.7 million per annum. An average of 167 acute beds would be freed each year.

Conclusions The use of clozapine in treatment-resistant schizophrenia saves lives, frees resources and is cost-effective.

Related articles in BJP:

Highlights of this issue

ELIZABETH WALSH
BJP 2003 182: 465-a23. [Full Text]  

This article has been cited by other articles:

				A. J Wheeler Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand Ann. Pharmacother., June 1, 2008; 42(6): 852 - 860. [Abstract] [Full Text] [PDF]

				J. S. Lamberti, D. Olson, J. F. Crilly, T. Olivares, G. C. Williams, X. Tu, W. Tang, K. Wiener, S. Dvorin, and M. B. Dietz Prevalence of the Metabolic Syndrome Among Patients Receiving Clozapine Am J Psychiatry, July 1, 2006; 163(7): 1273 - 1276. [Abstract] [Full Text] [PDF]

				G. Cirulli Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units Psychiatr. Bull., October 1, 2005; 29(10): 377 - 380. [Abstract] [Full Text] [PDF]

				J. Bouch and J. J. Marshall Suicide risk: structured professional judgement Advan. Psychiatr. Treat., March 1, 2005; 11(2): 84 - 91. [Abstract] [Full Text] [PDF]

				A. A. Woodall, D. B. Menkes, T. R. Trevelyan, and C. P. Lanceley A study of clozapine and long-term hospitalisation rates Psychiatr. Bull., August 1, 2004; 28(8): 285 - 288. [Abstract] [Full Text] [PDF]

				O. Howes, R. Ohlsen, and L. S. Pilowsky Effect of clozapine on mortality The British Journal of Psychiatry, November 1, 2003; 183(5): 460 - 460. [Full Text] [PDF]